Alnylam Pharmaceuticals, Inc. (ALNY) Stock

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is led by CEO Yvonne L. Greenstreet, employs 2,230 people, headquartered in Cambridge, US, publicly traded since 2004.

Alnylam Pharmaceuticals, Inc. (ALNY) stock trades at $231.83 with a market capitalization of $31.02B. The stock is valued at a price-to-earnings (P/E) ratio of 36.02, price-to-book of 21.62, price-to-sales of 6.12. Over the past 52 weeks the stock has ranged between $197.81 and $495.55, and currently trades 53.2% below its 52-week high.

On profitability, Alnylam Pharmaceuticals, Inc. generates a return on equity (ROE) of 93.61%, above the typical market range of roughly 12-15%, return on capital employed of 24.71%, an operating margin of 13.52%, a net profit margin of 16.82%.

In its most recent fiscal year, Alnylam Pharmaceuticals, Inc. reported annual revenue of $3.7B, net profit of $314.0M. Revenue grew at an average annual rate of 49.8% over the last 5 fiscal years.

The balance sheet shows a debt-to-equity ratio of 0.94, a current ratio of 2.76, total assets of $5.0B, $1.7B in cash and equivalents.

ALNY has a beta of 0.30 (historically less volatile than the overall market).